[Predictive biomarkers in colorectal cancer]. / Les biomarqueurs prédictifs dans le cancer colorectal.
Rev Med Suisse
; 5(211): 1513-8, 2009 Jul 15.
Article
en Fr
| MEDLINE
| ID: mdl-19694362
ABSTRACT
While for many years the diagnosis and therapy of colon cancer did not change drastically, recently new drugs (irinotecan and oxaliplatin, used in adjuvant or neo-adjuvant approaches) and even more recently the introduction of therapies targeting the epidermal growth factor receptor (EGFR) through the monoclonal antibodies cetuximab and panitumumab, are revolutionizing the field. The finding that only patients with a tumor with a wild type (non mutated) KRAS gene respond to anti-EGFR therapy has also affected the way pathologists address colorectal cancer. Molecular analysis of the KRAS gene has become almost a routine in a very short period of time. Pathologists will have to be prepared for a new era from standard morphology based diagnostic procedures to the prediction of response to therapy using molecular tools.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Colorrectales
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
Fr
Revista:
Rev Med Suisse
Asunto de la revista:
MEDICINA
Año:
2009
Tipo del documento:
Article